Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso
Rouamba et al.,
Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment..,
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.02.034, NCT04445441
Retrospective 863 COVID-19 patients in Burkina Faso, showing lower mortality, lower progression for outpatients, and faster viral clearance with HCQ/CQ treatment. Only the lower mortality was statistically significant.
NCT04445441 (history).
risk of death, 80.0% lower, HR 0.20, p < 0.001, treatment 20 of 336 (6.0%), control 24 of 73 (32.9%), NNT 3.7, adjusted per study, inpatients, multivariable, Cox proportional hazards.
|
risk of progression, 20.0% lower, HR 0.80, p = 0.43, treatment 75 of 745 (10.1%), control 19 of 118 (16.1%), adjusted per study, all patients, multivariable, Cox proportional hazards.
|
risk of progression, 73.0% lower, HR 0.27, p = 0.05, treatment 23 of 399 (5.8%), control 4 of 33 (12.1%), adjusted per study, outpatients, multivariable, Cox proportional hazards, early treatment result.
|
risk of progression, 7.0% higher, HR 1.07, p = 0.83, treatment 52 of 347 (15.0%), control 15 of 85 (17.6%), adjusted per study, inpatients, multivariable, Cox proportional hazards.
|
time to viral clearance, 30.6% lower, HR 0.69, p = 0.26, treatment 746, control 118, adjusted per study, inverted to make HR<1 favor treatment, all patients, propensity score matching, multivariable, Cox proportional hazards, primary outcome.
|
time to viral clearance, 13.0% lower, HR 0.87, p = 0.29, treatment 746, control 118, adjusted per study, inverted to make HR<1 favor treatment, all patients, without PSM, multivariable, Cox proportional hazards, primary outcome.
|
time to viral clearance, 21.3% lower, HR 0.79, p = 0.37, treatment 399, control 33, adjusted per study, inverted to make HR<1 favor treatment, outpatients, multivariable, Cox proportional hazards, primary outcome, early treatment result.
|
time to viral clearance, 13.8% lower, HR 0.86, p = 0.37, treatment 345, control 86, adjusted per study, inverted to make HR<1 favor treatment, inpatients, multivariable, Cox proportional hazards, primary outcome.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Rouamba et al., 26 Feb 2022, retrospective, Burkina Faso, peer-reviewed, mean age 42.2, 17 authors, study period 9 March, 2020 - 31 October, 2020, dosage 200mg tid days 1-10, HCQ 200mg tid daily or CQ 250mg bid daily, trial
NCT04445441 (history).
Abstract: Journal Pre-proof
Assessment of Recovery Time, Worsening and Death, among
COVID-19 inpatients and outpatients, under treatment with
Hydroxychloroquine or Chloroquine plus Azithromycin Combination
in Burkina Faso
Toussaint Rouamba , Esperance Ouédraogo , Houreratou Barry ,
Nobila Valentin Yaméogo , Apoline Sondo , Rainatou Boly ,
Jacques Zoungrana , Abdoul Risgou Ouédraogo ,
Marc Christian Tahita , Armel Poda , Arnaud Eric Diendéré ,
Abdoul-Salam Ouedraogo , Innocent Valea , Isidore Traoré ,
Zekiba Tarnagda , Maxime K. Drabo , Halidou Tinto , on behalf of
the CHLORAZ study group
PII:
DOI:
Reference:
S1201-9712(22)00111-4
https://doi.org/10.1016/j.ijid.2022.02.034
IJID 6025
To appear in:
International Journal of Infectious Diseases
Received date:
Revised date:
Accepted date:
29 December 2021
13 February 2022
15 February 2022
Please cite this article as: Toussaint Rouamba , Esperance Ouédraogo , Houreratou Barry ,
Nobila Valentin Yaméogo ,
Apoline Sondo ,
Rainatou Boly ,
Jacques Zoungrana ,
Abdoul Risgou Ouédraogo ,
Marc Christian Tahita ,
Armel Poda ,
Arnaud Eric Diendéré ,
Abdoul-Salam Ouedraogo , Innocent Valea , Isidore Traoré , Zekiba Tarnagda , Maxime K. Drabo ,
Halidou Tinto , on behalf of the CHLORAZ study group, Assessment of Recovery Time, Worsening
and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine
or Chloroquine plus Azithromycin Combination in Burkina Faso, International Journal of Infectious
Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.02.034
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
Highlights
Hydroxychloroquine+azithromycin (HCQ+AZ) did not reduce recovery time in COVID19
HCQ+AZ had no effect on the risk of worsening or transfer to the intensive care
The use of HCQ+AZ appeared to be associated with lower mortality rates
1
Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and
outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin
Combination in Burkina Faso
Toussaint Rouambaa*ǂ, Esperance Ouédraogoaǂ, Houreratou Barryb, Nobila Valentin
Yaméogoc, Apoline Sondoc, Rainatou Bolyd, Jacques Zoungranad, Abdoul Risgou
Ouédraogoe, Marc Christian Tahitaa, Armel Podad, Arnaud Eric Diendéréf, Abdoul-Salam
Ouedraogod, Innocent Valeaa, Isidore Traoréb, Zekiba Tarnagdaa, Maxime K Draboa and
Halidou Tintoa on behalf of the CHLORAZ study group.
a
Institut de Recherche en Sciences de la Santé, CNRST (IRSS- CNRST), Burkina Faso ;
b
Institut National de Santé Publique – Centre Muraz, Bobo-Dioulasso, Burkina Faso ;
c
Centre Hospitalier Universitaire Yalgado Ouédraogo, Ouagadougou, Burkina Faso ;
d
Centre Hospitalier Universitaire Sourou Sanon, Bobo-Dioulasso, Burkina..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit